While mTOR inhibitor everolimus has been registered in endocrine treatment-resistant advanced breast cancer and is under investigation in high-risk early breast cancer41, several AKT inhibitors are currently evaluated in advanced breast cancer, including endocrine treatment-resistant luminal disease42. Here, AKT1 is linked to breast carcinoma.